Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Conference News
Plain English
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Research News
back to News Search
Some Antipsychotic Drugs Impair Glucose Metabolism
Article appears by special arrangement with Alzheimer Research Forum. See original article with additional links/commentary.

7 January 2005. A report in the January issue of the Archives of General Psychiatry reinforces earlier observations that some antipsychotic drugs may increase the risk for, or even cause, diabetes in patients with schizophrenia. Since these drugs are often prescribed to patients with Alzheimer disease, and given the evidence of a link between diabetes and AD, this issue may become an important one in the AD clinical world, as well.

Psychiatrists have reported a trend toward greater incidence of type 2 ("insulin-resistant") diabetes mellitus in schizophrenia patients who take some of the newer, so-called "atypical," antipsychotic drugs. However, it is unclear whether this would be a direct effect of the drugs on glucose metabolism, or a secondary effect of the drugs promoting diabetes risk factors such as obesity or lipid abnormalities. David C. Henderson and colleagues at Massachusetts General Hospital and Harvard University assessed glucose function in a group of 36 non-obese patients with schizophrenia. They found that the atypical drugs olanzapine and clozapine increase insulin resistance and impair glucose effectiveness, relative to the drug risperidone, also in the atypical category. Since these patients were not obese, and had no differences in their lipid levels among the three drug groups, the researchers suggest that the drugs affect glucose metabolism directly.

Insulin resistance is the failure of cells to respond to insulin's signals to take up glucose from the blood, and it represents a major risk factor for type 2 diabetes. But interestingly, it may also be a risk factor for AD (see Alzheimer Research Forum related news story). The possibility that elderly patients taking antipsychotic drugs for behavioral symptoms, especially due to dementia, may be at increased risk of diabetes has been noted by some researchers (Lee et al., 2004). The doses given to these patients are typically less than those taken by younger people with schizophrenia, but altered pharmacokinetics may put older people at relatively greater risk.

Regarding possible mechanisms, the authors note, "The lower glucose effectiveness values observed in patients treated with clozapine and olanzapine could result from several mechanisms, including reduced functioning of glucose transporters or an impairment in the suppression of hepatic glucose production." However, they also point out the possibility that schizophrenia itself might be associated with insulin resistance and diabetes, independent of any effect of the drugs.—Hakon Heimer (Alzheimer Research Forum).

Reference:
Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, Weber MT, Anderson EJ, Allison DB, Daley TB, Schoenfeld D, Goff DC. Glucose Metabolism in Patients With Schizophrenia Treated With Atypical Antipsychotic Agents: A Frequently Sampled Intravenous Glucose Tolerance Test and Minimal Model Analysis. Arch Gen Psychiatry. 2005 Jan;62(1):19-28. Abstract

 
Comments on News and Primary Papers
Comment by:  James Manning IV
Submitted 25 November 2005 Posted 25 November 2005

This study is thoughtful and balanced, and driven by evidence.

View all comments by James Manning IV

Comment by:  Patricia Estani
Submitted 27 November 2005 Posted 28 November 2005
  I recommend the Primary Papers
Submit a Comment on this News Article
Make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Affiliation  
Country or Territory  
*Login Email Address  
*Confirm Email Address  
*Password  
*Confirm Password  
Remember my Login and Password?  
Get SRF newsletter with recent commentary?  
 
Enter the code as it is shown below:
This code helps prevent automated registrations.

Please note: A member needs to be both registered and logged in to submit a comment.

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


SRF News
SRF Comments
Text Size
Reset Text Size
Email this pageEmail this page

Share/Bookmark
Copyright © 2005- 2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright